An interventional study of Local Anesthesia (lidocaine hydrochloride) in Localised Prostate Cancer, sponsored by Koelis. Active, not recruiting at 2 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Koelis · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Prostatic Neoplasms with a site in Belgium — 42 open to participants now, 77 under way, 33 of them phase 3. Prostatic Neoplasms · Belgium.
Among the 236 studies in Prostatic Neoplasms with a site in Belgium, this one is the 195th largest by enrollment of the 206 interventional ones that give a count, is one of 9 that started in 2026, is one of 31 with no phase, reaches primary completion later than 47 of the 76 other live ones, and was the 234th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →42 of the 236 studies in Prostatic Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Belgium, United States, Australia and 21 more countries
Ages 18+ · Men only
BioNTech SE · Sites in Belgium, United States, Australia and 7 more countries
Ages 18+ · Men only
Jules Bordet Institute · Sites in Belgium
Men only
Bayer · Sites in Belgium, Finland, France and 13 more countries
Ages 18+ · Men only
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 18+ · Men only
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 59 · Phase 3 102 · Phase 4 6
First in 1992; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 283 across the 206 interventional studies, 805 across the 27 observational. Of the 152 that completed or were terminated, 78 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 236 have an industry lead sponsor. The 10 most frequent:
Koelis is the lead sponsor of 2 studies on the registry; none are open to participants now.
Koelis has 2 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Prostatic Neoplasms with a site in Belgium that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT05352178Phase 3Universitaire Ziekenhuizen KU LeuvenMetastasis-directed Therapy for Oligorecurrent Prostate Cancer | 2027-04-25 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 236 studies in Prostatic Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the feasibility of performing a focal Targeted Microwave Ablation (TMA) procedure using Koelis TMA® under local anesthesia in patient with localized prostate cancer.
Eligible patients will undergo the procedure under local anesthesia instead of general anesthesia or deep sedation as part of their routine clinical care.
The primary objective is to assess the feasibility of completing the procedure under local anesthesia, defined by the proportion of patients in whom the procedure is successfully completed under local anesthesia. Secondary objectives include the assessment of safety, ease of performance, patient satisfaction, and the use of analgesic medication.
This study is designed as a feasibility clinical investigation conducted in a routine clinical practice setting.
This clinical investigation is a prospective feasibility study designed to evaluate the feasibility of performing a focal Targeted Microwave Ablation (TMA) procedure using Koelis TMA® under local anesthesia in patient with localized prostate cancer. Koelis TMA® is a CE-marked medical device use without any modification to the device's intended use.
The study will be conducted in a routine clinical care setting. Eligible patients requiring the procedure will be included after providing informed consent.
The study consists of four visits. At the inclusion visit (Visit 0), patient eligibility will be confirmed and baseline data will be collected. The intervention will be performed during Visit 1 under local anesthesia according to standard clinical practice. A follow-up phone call (Visit 2) will be conducted 7 days after the procedure (±2 days) to assess safety and tolerability data. The end-of-study visit (Visit 3) will take place 1 month after the intervention (±7 days) during a routine follow-up consultation.
The primary objective of the study is to assess the feasibility of performing the procedure under local anesthesia. Feasibility will be evaluated by the proportion of patients in whom the procedure is successfully completed under local anesthesia. If the patient presents marked discomfort, pain, or any other symptoms that make the continuation of the procedure inappropriate, it may be interrupted at his request or at the initiative of the investigator. Local anesthesia can therefore be converted to general anesthesia or deep sedation to allow treatment to continue.
Secondary objectives include the assessment of procedure tolerability, safety, ease of performance as assessed by the operator, patient satisfaction related to anesthesia, and the amount of analgesic or pain medication administered during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient undergoing the focal targeted microwave ablation procedure performed under local anesthesia using the Koelis TMA®
Procedure: Local Anesthesia (lidocaine hydrochloride)
Participants will receive the focal treatment performed with Koelis TMA® under local anesthesia
Feasibility of focal TMA therapy under local anesthesia in patients with localized prostate cancer
Feasibility will be assessed by the rate of complete procedure performed under local anesthesia, defined as the proportion of patients in whom the procedure is completed under local anesthesia without the unplanned use of general anesthesia or sedation or premature termination of treatment
Time frame: Day 0 - Intervention
Immediate Patient satisfaction regarding the procedure under local anesthesia
The patient's satisfaction regarding the TMA procedure will be assessed by a questionnaire after the procedure
Time frame: Day 0 - Intervention
1 month patient satisfaction regarding the procedure under local anesthesia
The patient's satisfaction regarding the TMA procedure will be assessed by a questionnaire 1 month after the procedure
Time frame: 1 month
Ease of performing the procedure from the operator's point of view
The ease of performing the procedure will be evaluated by a score given by the operator (1: very easy; 2: easy; 3: moderate; 4: difficult, 5: very difficult).
Time frame: Day 0 - Intervention
Patient's level of pain at the time of administration of local anesthesia
The patient's average pain level will be assessed during the administration of local anesthesia by a numerical pain rating scale from 0 to 10.
Time frame: Day 0 - Intervention
Patient's pain level during the TMA treatment,
The patient's average pain level will be assessed during microwave ablation via a numerical pain rating scale from 0 to 10.
Time frame: Day 0 - Intervention
To assess the patient's level of pain after treatment,
The patient's average pain level will be assessed 1 hour after treatment via a numerical pain rating scale from 0 to 10.
Time frame: Day 0 - Intervention
To evaluate the duration of the different stages of the procedure,
Description of the duration of the different stages of the ablation procedure will be evaluated by: 1. The duration of the local anesthesia (minutes) 2. Microwave ablation treatment duration (minutes) 3. The duration of the intervention (minutes) (start-end of the procedure) 4. The time spent by the patient in the hospital post-procedure (hours)
Time frame: Day 0 - Intervention
Success of the completion of the procedure
The success of the completion/procedure will be assessed by the percentage of recovery of the lesion to be treated by microwave ablations
Time frame: Day 0 - Intervention
Feasibility of performing a TMA procedure in ambulatory setting
The feasibility of ambulatory treatment will be assessed based on the percentage of hospitalizations lasting less than 12 hours.
Time frame: Day 0 - Intervention
Tolerance of performing the procedure under local anesthesia,
Safety will be assessed by the number and severity of procedure-related adverse events, collected throughout the duration of the study
Time frame: 1 month
Amount of medication received by the patient
The amount of medication received as measured by the amount of analgesic/painkiller received by the patient throughout the duration of the study
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.
Of 58 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 11 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Jun 2026 → Jul 2026, primary completion May 2027 → Jun 2027 and completion Jun 2027 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.